Pranoprofen benefits dry eyes

Article

Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells.

Topical pranoprofen 0.1% reduces the ocular signs and symptoms of dry eyes and decreases inflammatory markers of conjunctival epithelial cells, according to a study in the latest journal of Cornea.

Dr X. Liu et al., Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, randomized 60 patients with dry eye into two groups.

Group 1 was administered topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%, while group 2 received sodium hyaluronate without pranoprofen. The outcome measures included ocular surface disease index (OSDI), tear film break-up time (TBUT), Schirmer I test results, ocular surface staining (OSS) results and conjunctival HLA-DR expression.

Group 1 demonstrated a significantly lower OSDI, OSS, and HLA-DR-positive cells, compared to group 2. However, TBUT was significantly longer in group 1 than group 2. On day 30 of the follow-up OSS differences between the group decreased in significance, but there were continued differences in OSDI, TBUT and HLA-DR expression between group 1 and 2.

On postoperative days 15 and 30 OSDI, TBUT and HLA-DR expression in group 1 demonstrated significant improvement, compared with results achieved in group 2. There were no significant effects in either group in the Schirmer test I values at days 15 and 30.

The abstract for this study can be found here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.